Abstract

In vitro Model For Immune Mediated Liver Injury Predictions

Neeraja Idamakanti, Principal Scientist, Takeda Pharmaceuticals

Despite recent advances in understanding of drug-induced liver injury (DILI), many aspects of its immune-mediated pathophysiology and clinical impact remain unclear. The inflammatory phenotype can be attributed to the innate or adaptive immune responses generated by infiltrating immune cells – which until now have never been successfully integrated into a functional 3D liver microtissue.  We developed immune mediated DILI model using human liver micro tissues with HLA matched PBMCs for prediction of clinical hepatotoxicity.